EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSLBEG00000019131
Gene Symbol: CACNA1B
1 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSLBEG00000008275
Gene Symbol: CACNA1D
2 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSLBEG00000004901
Gene Symbol: CACNA1E
1 Cross references
206 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSLBEG00000004509
Gene Symbol: CACNA1H
3 Cross references
204 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSLBEG00000012094
Gene Symbol: CNR1
3 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSLBEG00000015231
Gene Symbol: CNR1
4 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 2-Like

Ensembl ID : ENSLBEG00000008175
Gene Symbol: LOC109983727
3 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSLBEG00000016859
Gene Symbol: CA12
3 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSLBEG00000026406
Gene Symbol: CA14
3 Cross references
210 Possible Orthologues:

Carbonic Anhydrase 4

Ensembl ID : ENSLBEG00000016643
Gene Symbol: CA4
3 Cross references
212 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSLBEG00000000709
Gene Symbol: LOC109985302
3 Cross references
79 Possible Orthologues:

Carbonic Anhydrase 5b, Mitochondrial-Like

Ensembl ID : ENSLBEG00000008597
Gene Symbol: LOC109991852
3 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).